Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 30 systematic review(s)/meta-analysis(es). ^[1-30]
• Erenumab significantly reduces monthly migraine days (MMDs), with a mean reduction of 1.1 days at 28 mg, 1.4 days at 70 mg, and 1.8 days at 140 mg compared to placebo, showing effectiveness in both episodic and chronic migraines.
• Erenumab demonstrates a 50% response rate, meaning a significant proportion of patients experience at least a 50% reduction in MMDs, comparable to other calcitonin gene-related peptide antibodies (CGRP) monoclonal antibodies like fremanezumab and galcanezumab.
• Erenumab is effective in specific migraine types, such as menstrual migraines, and in patients with treatment-resistant or difficult-to-treat migraines, including those with prior preventive therapy failures.
• Comparatively, erenumab is effective, though not necessarily superior to other CGRP monoclonal antibodies like fremanezumab and galcanezumab, with fremanezumab 225 mg monthly showing particular efficacy in some analyses.
• Erenumab is generally well-tolerated, with common adverse events including injection-site reactions, constipation, and muscle spasms, occurring more frequently than placebo.
• Serious adverse events (SAEs) were rare and showed no significant difference compared to placebo, with no deaths directly attributed to erenumab in the studied cohorts.
• Erenumab’s safety profile is comparable to other CGRP monoclonal antibodies, such as galcanezumab, fremanezumab, and eptinezumab, with fewer cognitive and sensory-related adverse events than topiramate.
• Erenumab demonstrated effectiveness across diverse populations, including 85.1% female participants, older adults (≥60 years) with no increased adverse events compared to younger populations, and patients with prior preventive treatment failures, showing significant reductions in monthly migraine days and high responder rates in these subgroups.